“I would like to stress the need of focusing dissemination of information on what is HIV and not the figures because we need to change the mentality of our people.”.
1. In this randomized controlled trial, among patients living with human immunodeficiency virus (HIV) at low-to-moderate risk of cardiovascular disease, pitavastatin calcium was superior to placebo in reducing the risk of a major adverse cardiovascular event (MACE). 2. The trial was stopped early due to evidence of the efficacy and safety of pitavastatin. Evidence Rating
“It’s been so long that I’ve been on medication that most of the time I forget that I have HIV. ART allows individuals like me to maintain healthy immune systems, reduce opportunistic infections. It also reduces my chances of transmitting it,” he said..
1. In the randomized controlled trial, dolutegravir treatment was noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI) for treating human immunodeficiency virus (HIV). 2. Dolutegravir treatment for HIV was not associated with an increased risk of adverse events as compared to ritonavir-boosted treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: Currently, the World Health Organization